Skip to main content
Journal cover image

Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.

Publication ,  Journal Article
Legro, RS; Barnhart, HX; Schlaff, WD; Carr, BR; Diamond, MP; Carson, SA; Steinkampf, MP; Coutifaris, C; McGovern, PG; Cataldo, NA; Gosman, GG ...
Published in: J Clin Endocrinol Metab
March 2008

CONTEXT: Clomiphene and insulin sensitizers such as metformin are used to induce ovulation in polycystic ovary syndrome (PCOS), but the ovulatory response is variable, and the causes of this variation are poorly understood. OBJECTIVE: Our objective was to identify predictive genetic polymorphisms and other determinants of ovulatory response. DESIGN: This was a substudy of a multicenter randomized clinical trial. SETTING: This study was performed at academic medical centers and their affiliates. PARTICIPANTS: A total of 312 women with PCOS were included in the study. MAIN OUTCOME MEASURES: Historical, biometric, biochemical, and genetic parameters were performed. RESULTS: We found that the C allele of a single nucleotide polymorphism in the STK11 gene (expressed in liver; also known as LKB1) was associated with a significantly decreased chance of ovulation in PCOS women treated with metformin. In an analysis of ovulation per cycle, the adjusted odds ratio (OR) comparing the C/C genotype to the G/G genotype was 0.30 [95% confidence interval (CI) 0.14, 0.66], and the OR for the C/G genotype vs. the G/G genotype was also 0.30 (95% CI 0.14, 0.66). In an analysis of metformin-treated subjects, we found that the percentage of women who ovulated increased with the number of G alleles present: 48% (10 of 21) of C/C women, 67% (32 of 48) of C/G women, and 79% (15 of 19) of G/G women ovulated. We also found that increased frequency of ovulation was associated with lower body mass index (BMI) [adjusted OR of 2.36 (95% CI 1.65, 3.36) and 2.05 (95% CI 1.46, 2.88), respectively, for comparisons of BMI less than 30 vs. BMI equal to or more than 35, BMI 30-34 vs. BMI equal to or more than 35, in the analysis of ovulation per cycle], a lower free androgen index (FAI) [adjusted OR of 1.59 (95% CI 1.17, 2.18) for FAI<10 vs. FAI>or=10], and a shorter duration of attempting conception [adjusted OR of 1.63 (95% CI 1.20, 2.21) for<1.5 vs.>or=1.5 yr]. CONCLUSIONS: We have demonstrated that a polymorphism in STK11, a kinase gene expressed in liver and implicated in metformin action, is associated with ovulatory response to treatment with metformin alone in a prospective randomized trial. The interaction with the effects of changes in modifiable factors (e.g. BMI or FAI) requires further study.

Duke Scholars

Published In

J Clin Endocrinol Metab

DOI

ISSN

0021-972X

Publication Date

March 2008

Volume

93

Issue

3

Start / End Page

792 / 800

Location

United States

Related Subject Headings

  • Protein Serine-Threonine Kinases
  • Polymorphism, Single Nucleotide
  • Polycystic Ovary Syndrome
  • Ovulation
  • Metformin
  • Humans
  • Genotype
  • Female
  • Endocrinology & Metabolism
  • Double-Blind Method
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., … Reproductive Medicine Network. (2008). Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab, 93(3), 792–800. https://doi.org/10.1210/jc.2007-1736
Legro, Richard S., Huiman X. Barnhart, William D. Schlaff, Bruce R. Carr, Michael P. Diamond, Sandra A. Carson, Michael P. Steinkampf, et al. “Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.J Clin Endocrinol Metab 93, no. 3 (March 2008): 792–800. https://doi.org/10.1210/jc.2007-1736.
Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab. 2008 Mar;93(3):792–800.
Legro, Richard S., et al. “Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.J Clin Endocrinol Metab, vol. 93, no. 3, Mar. 2008, pp. 792–800. Pubmed, doi:10.1210/jc.2007-1736.
Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Ewens KG, Spielman RS, Leppert PC, Myers ER, Reproductive Medicine Network. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab. 2008 Mar;93(3):792–800.
Journal cover image

Published In

J Clin Endocrinol Metab

DOI

ISSN

0021-972X

Publication Date

March 2008

Volume

93

Issue

3

Start / End Page

792 / 800

Location

United States

Related Subject Headings

  • Protein Serine-Threonine Kinases
  • Polymorphism, Single Nucleotide
  • Polycystic Ovary Syndrome
  • Ovulation
  • Metformin
  • Humans
  • Genotype
  • Female
  • Endocrinology & Metabolism
  • Double-Blind Method